trial · primary record
Optimized neoantigen synthetic long peptide vaccine
Pancreas Cancer
| Phase | Phase 1 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 33 |
| Primary completion | 2027-10-06 |
| Primary endpoint | Safety of Neoantigen SLP Vaccine as Measured by Number of Subjects Experiencing Each Type of Adverse Event |
| Registry ID | NCT05111353 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:55:47.215Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT05111353
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.